GlaxoSmithKline to buy San Mateo-based Sierra Oncology for $1.9B
April 13, 2022 at 10:31 AM EDT
Glaxo is paying a 39% premium for the rare cancer-focused biotech whose stock has already shot up 82% this year.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|